Roy Daniel Pollom, MD

home / authors / roy-daniel-pollom-md

Articles

Biosimilars and Follow-on Biologics

Biosimilars and Follow-on Biologics

Michael McShea, RPH;Mark Borns, PharmD;Roy Daniel Pollom, MD
September 28th 2017

Pharmacists must be experts on follow-on biologics (FOBs), including biosimilars, so they can provide education to health professionals about safe prescribing and use, which ultimately affects patient care.

Read More

Biosimilars and Follow-on Biologics: A Pharmacist Opportunity

Biosimilars and Follow-on Biologics: A Pharmacist Opportunity

Michael McShea, RPH;Mark Borns, PharmD;Roy Daniel Pollom, MD
October 12th 2016

Health care practitioners need to prepare for myriad questions regarding biosimilars and follow-on biologic drugs as they enter the market.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD